the diminishing returns at higher doses is the honest part of the trial data that doesn't always make it into the popular coverage - the curves flatten as you go up in dose, which is why the practical ceiling is usually the tolerance limit not the efficacy limit. the receptor concern tends to come from bodybuilding circles where downregulation is a real thing and gets assumed to transfer, but the GLP-1 receptor mechanism doesn't work that way